08:00 , Dec 11, 2006 |  BC Week In Review  |  Clinical News

Sorivudine: Phase II data

In the Phase II ARYS-0502 trial, twice-daily treatment with ARYS-01 cream led to a 30% reduction in rash area during initial 3 days of treatment vs. placebo. The trial was not powered to show significance....
07:00 , Apr 11, 2005 |  BC Week In Review  |  Clinical News

JA-001: IND submitted

Janus submitted an IND to begin by mid-year an open-label, U.S. Phase I trial in 16 healthy volunteers. aRigen Inc. , Tokyo, Japan   Janus Pharmaceuticals Inc. , Pasadena, Calif.   Product: JA-001   Business:...
07:00 , Sep 27, 2004 |  BC Week In Review  |  Clinical News

WAP 8294A2: Phase I started

aRigen began a single-dose, double-blind, placebo-controlled, U.S. Phase I trial in 40 healthy volunteers. aRigen Inc. , Tokyo, Japan   Product: WAP 8294A2   Business: Infectious   Molecular target: NA   Description: Depsipeptide antibiotic  ...